



Drug Repurposing in Cancer Treatment and Impacting the Efficacy of Therapeutic Agents

Guest Editor:

Dr. Ravi P. Sahu

Department of Pharmacology
and Toxicology, Boonshoft
School of Medicine, Wright State
University, Fairborn, OH 45324,
USA

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editor

Cancer treatment remains an ongoing challenge, especially those malignancies which develop resistance to conventional therapeutic agents. While several tumor resistance mechanisms have been identified and strategies to overcome such mechanisms have resulted in improved responses of therapeutic agents, the overall survival benefits remain relatively low. Thus, new approaches to target those counter-regulatory pathways involved in impeding the efficacy of cancer therapy are being implicated to improve cancer treatment. Drug repurposing explores the use of existing investigational drugs with the known mechanisms of action for new clinical purposes, such as the treatment of human malignancies. There is an increased interest in exploring the potential of drug repurposing either alone, or in combination with conventional anticancer agents for cancer treatment. The focus of this Special Issue is to publish original research or review articles related to drug repurposing for cancer treatment, or improving the efficacy of therapeutic agents, including targeted therapy. Articles exploring the effectiveness of any drug repurposing candidates on any cancer models will be considered.

